Skip to main content
Premium Trial:

Request an Annual Quote

DiaGenic Gets $1.3M Grant for Alzheimer's Dx Project

NEW YORK (GenomeWeb News) – DiaGenic today said that it has received a NOK 7.8 million ($1.3 million) grant from the Norwegian Research Council for an Alzheimer's disease diagnostics program.

The Oslo, Norway-based firm said that the project is aimed at improving the robustness and reducing the cost of blood-based tests for Alzheimer's disease. Specifically, the project will focus on the use of microRNAs for early diagnosis of the disease.

Clinical samples will be sourced from DiaGenic's biobank and the HUNT Biosciences biobank, DiaGenic said.

"This new grant for development of blood based diagnostics for early Alzheimer's disease represents an important financial contribution," DiaGenic CEO Henrik Lund said in a statement.

Two months ago, DiaGenic inked a deal with GE Healthcare to develop a blood-based test using DiaGenic's gene expression profiling tools for the early detection of a disorder associated with Alzheimer's disease.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.